Impact of different dosing schedules on the immunogenicity of the human rotavirus vaccine in Infants in Pakistan: A randomized trial

Journal of Infectious Diseases

Volumn 210, Issue 11, 2014, Pages 1772-1779

  Ali, Syed Asad ^a   Kazi, Abdul Momin ^a   Cortese, Margaret M ^b   Fleming, Jessica A ^c   Parashar, Umesh D ^b   Jiang, Baoming ^b   McNeal, Monica Malone ^d   Steele, Duncan ^c,e   Bhutta, Zulfiqar ^a   Zaidi, Anita ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c PATH   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Pakistan; Rotarix; Rotavirus; Rotavirus vaccine; Vaccination schedule

Indexed keywords

IMMUNOGLOBULIN A; NEUTRALIZING ANTIBODY; ROTAVIRUS VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DEVELOPING COUNTRY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN ROTAVIRUS; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PAKISTAN; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS INFECTION; SEROCONVERSION; UNSPECIFIED SIDE EFFECT; VACCINATION; BLOOD; CHILD; CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; PRESCHOOL CHILD; ROTAVIRUS; ROTAVIRUS INFECTIONS;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN A; INFANT; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PAKISTAN; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 84922310944     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu335     Document Type: Article

References (17)

1. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:136-41.
2. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013; 382:209-22.
3. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
4. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33.
5. Patel MM, Parashar UD. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. J Infect Dis 2009; 200(suppl 1):S291-9.
6. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362: 289-98.
7. Lepage P, Vergison A. Impact of rotavirus vaccines on rotavirus disease. Expert Rev Anti Infect Ther 2012; 10:547-61.
8. Patel MM, Parashar UD, Santosham M, Richardson V. The rotavirus experience in Mexico: discovery to control. Clin Infect Dis 2013; 56:548-51.
9. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:615-23.
10. Steele AD, Reynders J, Scholtz F, et al. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. J Infect Dis 2010; 202(supp 1):S93-100.
11. The Treatment of diarrhoea: a manual for physicians and other senior health workers. Geneva: World Health Organization, 2005:44.
12. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 1998; 16:381-7.
13. Knowlton DR, Spector DM, Ward RL. Development of an improved method for measuring neutralizing antibody to rotavirus. J Virol Methods 1991; 33:127-34.
14. Zaman K, Sack DA, Yunus M, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009; 27: 1333-9.
15. Madhi SA, Kirsten M, Louw C, et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine 2012; 30(suppl 1):A44-51.
16. Cunliffe NA, Witte D, Ngwira BM, et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine 2012; 30(suppl 1):A36-43.
17. Ward RL, Knowlton DR, Zito ET, Davidson BL, Rappaport R, Mack ME. Serologic correlates of immunity in a tetravalent reassortant rotavirus vaccine trial. US Rotavirus Vaccine Efficacy Group. J Infect Dis 1997; 176:570-7.